Cancer Epidemiology Biomarkers & Prevention最新文献

{"title":"Body Composition at Diagnosis and Early Response in Pediatric Hodgkin Lymphoma.","authors":"Aman Wadhwa, Chen Dai, Sandra Kessel, Joshua S Richman, Wei Shen, Justine M Kahn, Sharon M Castellino, Kara M Kelly, Debra L Friedman, Smita Bhatia","doi":"10.1158/1055-9965.EPI-24-1231","DOIUrl":"10.1158/1055-9965.EPI-24-1231","url":null,"abstract":"<p><strong>Background: </strong>The association between skeletal, muscle, and adipose tissue (body composition) and early response using PET in pediatric Hodgkin lymphoma remains unstudied.</p><p><strong>Methods: </strong>Patients enrolled on Children's Oncology Group studies AHOD0031 (intermediate-risk Hodgkin lymphoma) and AHOD0831 (high-risk Hodgkin lymphoma) with digital abdominal CT scans at diagnosis and PET scans after 2 cycles (PET2) were included. Two consecutive slices at the third lumbar vertebra were identified, and skeletal muscle index (SMI; in cm2/m2) and total adipose tissue index (TATI; in cm2/m2) were calculated using sliceOmatic and height at diagnosis. SMI and TATI were divided into quintiles [Q1 (lowest) to Q5 (highest)]. Body mass index (BMI) was calculated using height and weight at diagnosis. The association between baseline body composition (SMI, TATI, and BMI) and positive PET2 was examined using logistic regression, adjusting for age at diagnosis, sex, race/ethnicity, stage, histology, bulk disease, and \"B\" symptoms.</p><p><strong>Results: </strong>Among 1,033 included patients, PET2 was positive in 314 (30.4%) patients. SMI was not associated with positive PET2. Extremes of TATI were associated with positive PET2, when compared with the middle TATI quintile [reference: Q3; ORQ1 = 1.63; 95% confidence interval (CI) = 1.03-2.60; P = 0.04; ORQ2 = 1.82; 95% CI = 1.17-2.82; P = 0.008; ORQ5 = 1.94; 95% CI = 1.23-3.05; P = 0.005]. The association between BMI in obesity range and positive PET2 trended toward significance (OR = 1.42; 95% CI = 0.98-2.04; P = 0.06; ref = normal weight).</p><p><strong>Conclusions: </strong>Extremes of adipose tissue at diagnosis influence early response among pediatric Hodgkin lymphoma.</p><p><strong>Impact: </strong>Validation of results from this study could inform studies investigating body composition-based chemotherapy dosing.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"560-567"},"PeriodicalIF":3.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Change in Metabolic Markers and the Risk of Skin Cancer: Results from the Lifelines Cohort Study in the Netherlands.","authors":"Michael Shimelash, Grigory Sidorenkov, Bert van der Vegt, Mathilde Jalving, Emöke Rácz, Geertruida H de Bock","doi":"10.1158/1055-9965.EPI-24-1235","DOIUrl":"10.1158/1055-9965.EPI-24-1235","url":null,"abstract":"<p><strong>Background: </strong>Skin cancers are the most common cancers in Caucasians, and their incidence is rising. Although metabolic and anthropometric markers play a role in cancer development, the relationship between metabolic and anthropometric changes in skin cancer remains unclear. This study aimed to examine possible associations between these changes and the risk of skin cancer.</p><p><strong>Methods: </strong>Participants without prior skin cancer history from the Northern Netherlands representative of the general population were included. Histopathology data were obtained from the Dutch Nationwide Pathology Database. Adjusted Cox regression analyzed associations between metabolic changes and time to pathology-confirmed skin cancer incidence over a 7-year follow-up, assessing overall skin cancer risk and subtypes, including melanoma and nonmelanoma skin cancer.</p><p><strong>Results: </strong>Out of 97,106 participants, 4,195 (4.3%) developed skin cancer. Decrease and increase in body mass index (BMI) were both associated with lower skin cancer risk: adjusted HRs (aHR) of 0.88 (0.80-0.98) and 0.78 (0.72-0.86), respectively. Triglyceride and waist-to-hip ratio decreases were also associated with lower risk: aHR: 0.89 (0.80-0.98) and 0.89 (0.83-0.98), respectively. Increase in Hemoglobin A1c (HbA1c) was associated with a higher risk in individuals below the age of 45 years at baseline: aHR: 1.21 (1.01-1.45). Subtype analysis showed an increase in BMI was associated with lower melanoma risk: aHR: 0.72 (0.58-0.91).</p><p><strong>Conclusions: </strong>Changes in BMI and decrease in triglycerides and waist-to-hip ratio are related to lower skin cancer risk, whereas an increase in HbA1c may elevate risk in individuals younger than 45 at baseline. These findings highlight the importance of non-sunlight-related risk factors for skin cancer prevention and the need for further research into underlying mechanisms.</p><p><strong>Impact: </strong>This study contributes to the broader understanding of how metabolic health impacts skin cancer development, offering potential avenues for targeted prevention strategies.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"598-609"},"PeriodicalIF":3.7,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11966110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Race/Ethnicity on the Association between Neighborhood Deprivation and Breast Cancer Outcomes among Kentucky Patients with Breast Cancer (2010-2022).","authors":"Breyanna Walker, Elinita Pollard, Sydney P Howard, V Morgan Jones, Kathleen L O'Connor, Eric B Durbin, Pamela C Hull, Samantha R Jones, Adebola Adegboyega, Xiaoqin Wang, Wendi A B Owen, Margaret M Szabunio, Lovoria B Williams, Justin X Moore","doi":"10.1158/1055-9965.EPI-24-1139","DOIUrl":"10.1158/1055-9965.EPI-24-1139","url":null,"abstract":"<p><strong>Background: </strong>Kentucky is within the top five leading states for breast cancer mortality nationwide. This study investigates the association between neighborhood socioeconomic disadvantage and breast cancer outcomes, including surgical treatment, radiotherapy, chemotherapy, and survival, and how associations vary by race and ethnicity in Kentucky.</p><p><strong>Methods: </strong>We conducted a retrospective cohort analysis using data from the Kentucky Cancer Registry for patients with breast cancer diagnosed between 2010 and 2017, with follow-up through December 31, 2022. We linked Kentucky Cancer Registry data with census tract data to examine the relationship between area deprivation index (ADI) and breast cancer outcomes. Logistic regression and Cox proportional hazards models analyzed binary outcomes and time-to-event data, respectively.</p><p><strong>Results: </strong>Women in the most disadvantaged (ADI fourth quartile) neighborhoods were more likely to be diagnosed at later stages (OR, 1.26; 95% confidence interval, 1.12-1.41) and 34% more likely to die from breast cancer (HR, 1.34; 95% confidence interval, 1.14-1.57) after adjusting for age, race, tobacco use, tobacco pack-years, marital status, insurance status, family history, stage at diagnosis, breast cancer subtype, and residence in Appalachia when compared with women living in the least disadvantaged neighborhoods (ADI first quartile).</p><p><strong>Conclusions: </strong>Women in disadvantaged neighborhoods had significantly higher odds of late-stage diagnosis and breast cancer death, regardless of race, indicating that neighborhood factors contribute to breast cancer disparities.</p><p><strong>Impact: </strong>Socioeconomic and neighborhood factors may contribute to breast cancer outcomes, suggesting the necessity for targeted interventions. Future research should explore the effectiveness of such interventions and investigate additional social determinants contributing to disparities.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"474-482"},"PeriodicalIF":3.7,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11966108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Waist Circumference, a Body Shape Index, and Molecular Subtypes of Colorectal Cancer: A Pooled Analysis of Four Cohort Studies.","authors":"Christos V Chalitsios, Georgios Markozannes, Christos Papagiannopoulos, Elom K Aglago, Sonja I Berndt, Daniel D Buchanan, Peter T Campbell, Yin Cao, Andrew T Chan, Niki Dimou, David A Drew, Amy J French, Peter Georgeson, Marios Giannakis, Stephen B Gruber, Marc J Gunter, Tabitha A Harrison, Michael Hoffmeister, Li Hsu, Wen-Yi Huang, Meredith A J Hullar, Jeroen R Huyghe, Brigid M Lynch, Victor Moreno, Christina C Newton, Jonathan A Nowak, Mireia Obón-Santacana, Shuji Ogino, Conghui Qu, Stephanie L Schmit, Robert S Steinfelder, Wei Sun, Claire E Thomas, Amanda E Toland, Quang M Trinh, Tomotaka Ugai, Caroline Y Um, Bethany Van Guelpen, Syed H Zaidi, Neil Murphy, Ulrike Peters, Amanda I Phipps, Konstantinos K Tsilidis","doi":"10.1158/1055-9965.EPI-24-1534","DOIUrl":"10.1158/1055-9965.EPI-24-1534","url":null,"abstract":"<p><strong>Background: </strong>Waist circumference (WC) and its allometric counterpart, \"a body shape index\" (ABSI), are risk factors for colorectal cancer; however, it is uncertain whether associations with these body measurements are limited to specific molecular subtypes of the disease.</p><p><strong>Methods: </strong>Data from 2,772 colorectal cancer cases and 3,521 controls were pooled from four cohort studies within the Genetics and Epidemiology of Colorectal Cancer Consortium. Four molecular markers (BRAF mutation, KRAS mutation, CpG island methylator phenotype, and microsatellite instability) were analyzed individually and in combination (Jass types). Multivariable logistic and multinomial logistic models were used to assess the associations of WC and ABSI with overall colorectal cancer risk and, in case-only analyses, to evaluate heterogeneity by molecular subtype, respectively.</p><p><strong>Results: </strong>Higher WC (ORper 5 cm = 1.06, 95% confidence interval, 1.04-1.09) and ABSI (ORper 1-SD = 1.07, 95% confidence interval, 1.00-1.14) were associated with elevated colorectal cancer risk. There was no evidence of heterogeneity between the molecular subtypes. No difference was observed regarding the influence of WC and ABSI on the four major molecular markers in proximal colon, distal colon, and rectal cancers, as well as in early- and late-onset colorectal cancers. Associations did not differ in the Jass-type analysis.</p><p><strong>Conclusions: </strong>Higher WC and ABSI were associated with elevated colorectal cancer risk; however, they do not differentially influence all four major molecular mutations involved in colorectal carcinogenesis but underscore the importance of maintaining a healthy body weight in colorectal cancer prevention.</p><p><strong>Impact: </strong>The proposed results have potential utility in colorectal cancer prevention.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"568-577"},"PeriodicalIF":3.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12132105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sample Size Estimations Based on Human Microbiome Temporal Stability Over 6 Months: A Shallow Shotgun Metagenome Sequencing Analysis.","authors":"Semi Zouiouich, Yunhu Wan, Emily Vogtmann, Carolina Porras, Christian C Abnet, Jianxin Shi, Rashmi Sinha","doi":"10.1158/1055-9965.EPI-24-0839","DOIUrl":"10.1158/1055-9965.EPI-24-0839","url":null,"abstract":"<p><strong>Background: </strong>Biological factors affect the human microbiome, highlighting the need for reasonably estimating sample sizes in future population studies.</p><p><strong>Methods: </strong>We assessed the temporal stability of fecal microbiome diversity, species composition, and genes and functional pathways through shallow shotgun metagenome sequencing. Using intraclass correlation coefficients (ICC), we measured biological variability over 6 months. We estimated case numbers for 1:1 or 1:3 matched case-control studies, considering significance levels of 0.05 and 0.001 with 80% power, based on the collected fecal specimens per participant.</p><p><strong>Results: </strong>The fecal microbiome's temporal stability over 6 months varied (ICC < 0.6) for most alpha and beta diversity metrics. Heterogeneity was seen in species, genes, and pathways stability (ICC, 0.0-0.9). Detecting an OR of 1.5 per SD required 1,000 to 5,000 cases (0.05 significance for alpha and beta; 0.001 for species, genes, and pathways) with equal cases and controls. Low-prevalence species needed 15,102 cases, and high-prevalence species required 3,527. Similar needs applied to genes and pathways. In a 1:3 matched case-control study with one fecal specimen, 10,068 cases were needed for low-prevalence species and 2,351 for high-prevalence species. For ORs of 1.5 with multiple specimens, cases needed for low-prevalence species were 15,102 (one specimen), 8,267 (two specimens), and 5,989 (three specimens).</p><p><strong>Conclusions: </strong>Detecting disease associations requires a large number of cases. Repeating prediagnostic samples and matching cases to more controls could decrease the needed number of cases for such detections.</p><p><strong>Impact: </strong>Our results will help future epidemiologic study designs and implement well-powered microbiome studies.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"588-597"},"PeriodicalIF":3.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12415979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143381429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clonal Hematopoiesis of Indeterminate Potential as a Predictor of Colorectal Cancer Risk: Insights from the UK Biobank Cohort.","authors":"Yongfeng Liu, Zhihui Xi, Jianlong Zhou, Fa Ling, Yucheng Zhang, Huajie Xie, Jiabin Zheng, Baijin Xia, Huolun Feng, Yong Li","doi":"10.1158/1055-9965.EPI-24-1342","DOIUrl":"10.1158/1055-9965.EPI-24-1342","url":null,"abstract":"<p><strong>Background: </strong>Clonal hematopoiesis of indeterminate potential (CHIP) has been shown to be associated with the occurrence of solid tumors, but its relationship with colorectal cancer still needs to be studied.</p><p><strong>Methods: </strong>We conducted a prospective matched case-control study using data from the UK Biobank, including 5,310 incident colorectal cancer cases and 26,550 controls matched for age, sex, and body mass index.</p><p><strong>Results: </strong>Analysis of the UK Biobank data revealed that the presence of CHIP was associated with an increased risk of colorectal cancer. The odds ratio (OR) for colorectal cancer in the presence of CHIP was 1.20 (P = 0.006). This association remained significant even after excluding participants with a family history of bowel cancer (multivariate OR, 1.19; P = 0.007). Subgroup analyses demonstrated that CHIP independently increased the risk of colorectal cancer in females (multivariate OR, 1.25; P = 0.018) and in individuals older than 60 years (multivariate OR, 1.17; P = 0.046). Gene-specific analyses revealed that mutations in TET2 and ATM were particularly significant in relation to colorectal cancer risk, with an OR of 1.62 (P = 0.002) for TET2 and 2.98 (P < 0.001) for ATM.</p><p><strong>Conclusions: </strong>Our findings indicate that CHIP is associated with an increased risk of colorectal cancer, particularly in individuals more than 60 years of age or in females.</p><p><strong>Impact: </strong>Screening for CHIP in the population may improve the early detection and diagnosis rates of colorectal cancer.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"405-411"},"PeriodicalIF":3.7,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Clinical Covariates on Serum miRNA Expression among Women without Ovarian Cancer.","authors":"Laura Wollborn, James W Webber, Stephanie Alimena, Sudhanshu Mishra, Chad B Sussman, Cameron E Comrie, Daniel G Packard, Marta Williams, Trinity Russell, Wojciech Fendler, Dipanjan Chowdhury, Kevin M Elias","doi":"10.1158/1055-9965.EPI-23-1355","DOIUrl":"10.1158/1055-9965.EPI-23-1355","url":null,"abstract":"<p><strong>Background: </strong>Serum miRNAs are potential biomarkers for ovarian cancer; however, many factors may influence miRNA expression. To understand potential confounders in miRNA analysis, we examined how sociodemographic factors and comorbidities, including known ovarian cancer risk factors, influence serum miRNA levels in women without ovarian cancer.</p><p><strong>Methods: </strong>Data from 1,576 women from the Mass General Brigham Biobank collected between 2012 and 2019, excluding subjects previously or subsequently diagnosed with ovarian cancer, were examined. Using a focused panel of 179 miRNA probes optimized for serum profiling, miRNA expression was measured by flow cytometry using the Abcam FirePlex assay and correlated with subjects' electronic medical records.</p><p><strong>Results: </strong>The study population broadly reflected the New England population. The median age of subjects was 49 years, 34% were current or prior smokers, 33% were obese (body mass index > 30 kg/m2), 49% were postmenopausal, and 11% had undergone prior bilateral oophorectomy. Significant differences in miRNA expression were observed among ovarian risk factors such as age, obesity, menopause, BRCA1 or BRCA2 germline mutations, or existence of breast cancer in family history. Additionally, miRNA expression was significantly altered by prior bilateral oophorectomy, hypertension, and hypercholesterolemia. Other variables, such as smoking; parity; age at menarche; hormonal replacement therapy; oral contraception; breast, endometrial, or colon cancer; and diabetes, were not associated with significant changes in the panel when corrected for multiple testing.</p><p><strong>Conclusions: </strong>Serum miRNA expression patterns are significantly affected by patient demographics, exposure history, and medical comorbidities.</p><p><strong>Impact: </strong>Understanding confounders in serum miRNA expression is important for refining clinical assays for cancer screening.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"385-393"},"PeriodicalIF":3.7,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141080821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Health Conditions among LGBTQ+ Cancer Survivors: Letter.","authors":"Di Zhao, Jie Liu","doi":"10.1158/1055-9965.EPI-24-1737","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-1737","url":null,"abstract":"","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":"34 3","pages":"448"},"PeriodicalIF":3.7,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-FDX1 Autoantibody as a Potential Biomarker for Non-Small Cell Lung Cancer Detection.","authors":"Jing Li, Xiaobin Cao, Lulu Zhang, Aichen Liu, Siyu Liu, Fengqi Chen, Yutong Li, Hanke Ma, Wenke Sun, Songyun Ouyang, Liping Dai, Jingjing Liu","doi":"10.1158/1055-9965.EPI-24-1096","DOIUrl":"10.1158/1055-9965.EPI-24-1096","url":null,"abstract":"<p><strong>Background: </strong>Autoantibodies can be readily identified prior to biopsy and may serve as valuable biomarkers for cancer detection. Ferredoxin 1 (FDX1) is a key regulator in the process of cuproptosis and affects the prognosis of lung cancer. In this study, we investigated whether the anti-FDX1 autoantibody could serve as a novel biomarker for the detection of non-small cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>A total of 1,155 plasma samples were divided into the verification and validation groups. The expression levels of the anti-FDX1 autoantibody in 414 patients with NSCLC, 327 patients with benign pulmonary nodules (BPN), and 414 normal controls (NC) were detected using ELISA. Western blotting and immunofluorescence analyses were performed to confirm the ELISA results.</p><p><strong>Results: </strong>Plasma anti-FDX1 autoantibody levels were significantly higher in patients with NSCLC than in patients with BPN and NCs in the verification and validation groups. The ELISA results were confirmed by Western blotting and immunofluorescence. The anti-FDX1 autoantibody distinguished NSCLC from NC and BPN with an AUC (95% confidence interval) of 0.806 (0.772-0.839) and 0.627 (0.584-0.670), respectively.</p><p><strong>Conclusions: </strong>Our study demonstrated the potential benefits of the anti-FDX1 autoantibody as a novel biomarker for NSCLC detection.</p><p><strong>Impact: </strong>These findings suggested that the anti-FDX1 autoantibody may facilitate the detection of NSCLC.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"439-447"},"PeriodicalIF":3.7,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential DNA Methylation in the Benign and Cancerous Prostate Tissue of African American and European American Men.","authors":"Meytal Chernoff, Kathryn Demanelis, Marc Gillard, Dayana Delgado, Kevin J Gleason, Meritxell Oliva, Lin Chen, Anthony Williams, Russel Z Szmulewitz, Donald J Vander Griend, Brandon L Pierce","doi":"10.1158/1055-9965.EPI-24-0288","DOIUrl":"10.1158/1055-9965.EPI-24-0288","url":null,"abstract":"<p><strong>Background: </strong>African American (AA) men are at increased risk of prostate cancer compared with European American (EA) men. Biological mechanisms, including epigenetics, likely contribute to this disparity, but prior studies have been limited by sample size, candidate gene approaches, or lack of epigenome-wide DNA methylation (DNAm) data.</p><p><strong>Methods: </strong>To improve our understanding of these mechanisms, we compared DNAm features distinguishing tumor and paired histologically benign tissue from 76 AA and 75 EA patients with prostate cancer. We generated genome-wide array-based DNAm data and conducted differential methylation analyses comparing tumor and benign tissues in each ancestry group. We then examined the predictive ability of our identified sites and differential methylation by ancestry group.</p><p><strong>Results: </strong>We identified 90,747 and 98,929 differentially methylated CpGs in AA and EA, respectively, with 76,400 common to both groups. We identified 6,267 genes with differentially methylated promoters common to both ancestries and 639 and 1,301 genes unique to AA and EA respectively, as well as differentially methylated pathways. Only 10 CpGs were needed to distinguish tumor from benign based on a receiver operating characteristic curve (AUC > 0.9), with differentially methylated CpGs in one ancestry accurately predicting tumor versus benign in the other group. We also identified ancestry-associated CpGs (89 in tumor, 423 in benign).</p><p><strong>Conclusions: </strong>Methylation features distinguishing tumor and benign were similar for EA and AA men; however, subtle differences were identified.</p><p><strong>Impact: </strong>Differences in tumor and ancestry-associated CpGs may reveal differential tumor growth strategies, an important area for future disparities research.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"428-438"},"PeriodicalIF":3.7,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}